Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Bone-targeted agents

5 evidence topics · 6 sources

Zoledronic acid versus placebo in metastatic prostate cancer
StudyPatients with a skeletal-related event, zoledronic acid 4 mgPatients with a skeletal-related event, placeboMedian days to first skeletal-related event, zoledronic acid 4 mgMedian days to first skeletal-related event, placeboHazard ratio for first skeletal-related event (95% CI)
Prostate cancer study“33%”“44%”“Not Reached”“321”“0.67 (0.49, 0.91)”